Related Experiment Video
Updated: Aug 7, 2026
Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models
Published on: June 16, 2022
Inhibition of cell proliferation by mitomycin C incorporated into P(HEMA) hydrogels
Diane A Blake1, Nurettin Sahiner, Vijay T John
1Department of Biochemistry, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Objectives:
The technique of mitomycin C (MMC) drug delivery and its application in glaucoma surgery are not standardized with resultant inconsistencies in the results. Also, one time application of MMC does not seem to have the same efficacy after glaucoma drainage device surgeries compared with trabeculectomies. This preliminary study examined the efficacy of a slow release form of MMC for its ability to inhibit cell proliferation in vitro.
Methods:
MMC was incorporated into 1% P(HEMA) hydrogels using a redox polymerization method. For some experiments, unreacted low molecular weight components were removed from the hydrogels before the MMC was incorporated. Sterile disks (8 mm) of each polymer sample were affixed to 60 mm tissue culture dishes, and the dishes were inoculated with COS-1 cells or early passage human conjunctival fibroblasts. After 7 days in culture, the number of cells in each dish was determined. Cell morphology was assessed in replicate cultures after fixation and staining.
Results:
Hydrogels with unreacted low molecular weight components slowed cell proliferation and induced morphologic changes. Early passage human conjunctival fibroblasts were more sensitive than COS-1 cells both to intrinsic contaminants in the hydrogels and to incorporated MMC. Once contaminants had been removed, MMC-loaded hydrogels inhibited conjunctival fibroblast proliferation in a dose-dependent fashion, with an IC50 of approximately 0.15 mg/g polymer.
Conclusions:
This study demonstrates that a slow release form of MMC can inhibit cell proliferation in vitro. Future experiments will focus upon the efficacy of this polymer-bound form during in vivo wound healing.
Insights
A novel slow-release form of mitomycin C (MMC) effectively inhibits cell proliferation in vitro. This polymer-bound MMC shows promise for future glaucoma surgeries, potentially improving outcomes in wound healing.
Area of Science:
- Ophthalmology
- Biomaterials Science
- Cell Biology
Background:
- Standardization of mitomycin C (MMC) delivery in glaucoma surgery is lacking, leading to inconsistent outcomes.
- Single-application MMC may have reduced efficacy in glaucoma drainage device surgeries compared to trabeculectomies.
Purpose of the Study:
- To evaluate the in vitro efficacy of a slow-release formulation of MMC in inhibiting cell proliferation.
- To investigate the potential of polymer-bound MMC for enhanced drug delivery in ophthalmic procedures.
Main Methods:
- Mitomycin C (MMC) was incorporated into poly(2-hydroxyethyl methacrylate) (P(HEMA)) hydrogels via redox polymerization.
- COS-1 cells and human conjunctival fibroblasts were cultured on hydrogel disks, with and without MMC, to assess cell proliferation and morphology.
- Removal of unreacted low molecular weight components from hydrogels was performed before MMC incorporation in some experiments.
Main Results:
- Hydrogels containing unreacted components inhibited cell proliferation and altered cell morphology.
- Human conjunctival fibroblasts demonstrated higher sensitivity to hydrogel contaminants and MMC than COS-1 cells.
- MMC-loaded hydrogels, after contaminant removal, exhibited dose-dependent inhibition of fibroblast proliferation with an IC50 of approximately 0.15 mg/g.
Conclusions:
- A slow-release formulation of MMC effectively inhibits cell proliferation in vitro.
- This polymer-bound MMC demonstrates potential for controlling wound healing in vivo.
- Further research is warranted to assess the in vivo efficacy of this sustained-release MMC delivery system.
